LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Seegene Launches KFDA-Approved COVID-19 Assay

By LabMedica International staff writers
Posted on 17 Mar 2020
Print article
Image: Allplex™ 2019-nCoV Assay (Photo courtesy of Seegene Inc.)
Image: Allplex™ 2019-nCoV Assay (Photo courtesy of Seegene Inc.)
Seegene Inc. (Seoul, South Korea) has received approval from the Korea Ministry of Food and Drug Safety for its novel coronavirus (COIVD-19) Real-time PCR assay for emergency use, following the recent obtaining of CE-IVD Mark. The company has begun offering the assays in Korea and across the world.

Seegene is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Its core enabling technologies - DPO™, TOCE™, and MuDT™ - are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility.

Seegene had launched a single-tube assay, Allplex™ 2019-nCoV Assay that identifies the three different target genes (E gene, RdRP gene and Ngene) designed based on the international recommended protocols posted by World Health Organization (WHO). The capability of a simultaneous test in a single-tube, compared to the existing multi-tube assays, greatly improves the efficiency in workflow, maximizing the throughput for a high volume test and minimizing the test cost.

Seegene's automated system with its auto analysis software provides test results in four hours and can perform thousands of tests a day. When used together with Seegene's other high multiplex respiratory assay portfolio that screens and identifies 19 respiratory viruses and seven pneumonia bacteria with similar symptoms, it is able to diagnose the cause accurately and promptly. Seegene is capable of manufacturing 100,000 COVID-19 tests a day in order to meet the demands from the market and international society.

"It is meaningful that our molecular diagnostic technology and product can contribute to the international community in need of this new virus," said Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "We are pleased to report KFDA approval of our COIVD-19 assay and are ready to support global healthcare organizations in need of our diagnostic solution."

Related Links:
Seegene Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more